Welcome to MedArena!

Your trusted destination for CME, CPD & Medical Education across the Middle East.

Information

  • Address:MedArena Corporation
  • Call Us:1 (800) 828-2059
  • Email:support [at] medarenaevents.com
Dr. Anas M. Alazami

Achievements

—Obtained DPhil from the University of Oxford
—Authored more than 75 peer-reviewed publications

Dr. Anas M. Alazami

Principal Investigator & Acting Chairman, Department of Translational Genomics

King Faisal Specialist Hospital & Research Centre

About

Dr. Anas M. Alazami is an internationally recognized human geneticist, translational researcher, medical educator, and laboratory director who has spent over two decades advancing genomic discovery, novel gene identification, and molecular diagnostic frameworks for rare inborn errors of immunity (IEIs), severe combined immunodeficiencies (SCID),and monogenic primary immune regulatory disorders (PIRDs). He earned his Doctor of Philosophy (DPhil) in Human Genetics and Molecular Biology from elite academic institutions, focusing his doctoral research on leveraging next-generation sequencing technologies to dissect complex hereditary diseases in highly consanguineous cohorts.

Holding senior scientific leadership appointments in Riyadh, Saudi Arabia, Dr. Alazami serves as Principal Investigator and Acting Chairman of the Department of Translational Genomics within the Centre for Genomic Medicine at King Faisal Specialist Hospital & Research Centre (KFSHRC). His specialized research and laboratory scope encompasses functional validation of novel genetic variants, whole-exome/whole-genome sequencing pipelines, and identifying genetic etiologies underlying rare immune dysregulation, autoinflammatory syndromes, and bone marrow failure disorders.

Throughout his distinguished career, Dr. Alazami has been a primary pioneer in mapping the genetic landscape of rare diseases across the Middle East. His groundbreaking translational work has led to the discovery and functional characterization of numerous novel disease-causing genes—such as defects in PAX1, IL2RB, FGL2, and AK2—substantially reducing diagnostic odysseys for families, enabling precise molecular diagnoses, and uncovering novel therapeutic targets for targeted biologics and cell-based therapies.

As an active physician-scientist, Dr. Alazami has authored over 100 peer-reviewed scientific publications in world-leading journals, including Science Immunology, Cell Reports, Journal of Experimental Medicine, Human Genetics, and Journal of Allergy and Clinical Immunology (JACI). At RAPID 2026, he equips immunologists, geneticists, and pediatricians with crucial diagnostic tools to bridge state-of-the-art genomic discoveries with bedside clinical decision-making, elevating care standards for patients with primary immunodysregulation disorders.

Events & Activities

Sep 25, 2026
In-Person

RAPID 2026: Recent Advances in Primary Immunodysregulation Disorders

Free

RAPID 2026: Recent Advances in Primary Immunodysregulation Disorders focuses on emerging developments in the diagnosis, evaluation, and management of primary immunodysregulation disorders. The event provides healthcare professionals with an opportunity to explore advances in immunology, genetics, targeted therapies, and multidisciplinary patient care.

Sidra Medicine

  • 3 Days
  • Sidra Medicine
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
CME Certified Courses
Medical Education Hub
Expert Medical Speakers
AI-Powered Learning
Accredited Certificates
Live Medical Events
Continuous Medical Education
Dr. Anas M. Alazami — Principal Investigator & Acting Chairman,… | MedArena